Antibiotic Resistance of Uropathogenic <i>Escherichia coli</i> Isolated from Patients with Urinary Tract Infections at the Urological Inpatient Facility of the Saratov Clinical Hospital

The aim of the work was to study the profile of antibiotic resistance of uropathogenic Escherichia coli strains isolated from patients with urinary tract infections in the urological inpatient facility of the clinical hospital in the Saratov city, depending on appurtenance to phylogenetic groups and subgroups, as well as O-serogroups.Materials and methods. We assessed sensitivity/resistance to 25 different antibacterial drugs in 102 strains of uropathogenic E. coli. The studies were carried out using the disk diffusion method. The production of extended spectrum beta-lactamases was evaluated by the double disk method. Carbapenemase output was determined using the CIM test. The PCR method was applied to determine appurtenance to phylogenetic groups and subgroups, O-serogroups, as well as the frequency of occurrence of the mcr‑1, mcr‑2, mcr‑3, mcr‑4, mcr‑5 genes encoding the proteins that mediate the development of resistance to colistin.Results and discussion. It has been established that all strains of uropathogenic E. coli are more or less resistant to antibacterial drugs. All studied 102 strains showed resistance to 23 antibacterial drugs from 8 functional groups. The resistance of uropathogenic E. coli had certain differences depending on belonging to phylogenetic groups and subgroups, O-serogroups. Strains of uropathogenic E. coli with high resistance (up to 100 %) belonged to the B23 phylogenetic group, the main representatives of which are cultures of the most common O-25 serogroup. The production of extended-spectrum beta-lactamases has been phenotypically confirmed for 69 (67.6 %) strains. No carbapenemaseproducing cultures were found in the study. The mcr‑1 and mcr‑2 genes encoding resistance to colistin have been identified in 3 uropathogenic E. coli strains (2.9 %)

Sex differences in the impact of ozone on survival and alveolar macrophage function of mice after Klebsiella pneumoniae infection

<p>Abstract</p> <p>Background</p> <p>Sex differences have been described in a number of pulmonary diseases. However, the impact of ozone exposure followed by pneumonia infection on sex-related survival and macrophage function have not been reported. The purpose of this study was to determine whether ozone exposure differentially affects: 1) survival of male and female mice infected with <it>Klebsiella pneumoniae</it>, and 2) the phagocytic ability of macrophages from these mice.</p> <p>Methods</p> <p>Male and female C57BL/6 mice were exposed to O₃or to filtered air (FA) (control) and then infected intratracheally with <it>K. pneumoniae </it>bacteria. Survival was monitored over a 14-day period, and the ability of alveolar macrophages to phagocytize the pathogen <it>in vivo </it>was investigated after 1 h.</p> <p>Results</p> <p>1) Both male and female mice exposed to O₃are significantly more susceptible to <it>K. pneumoniae </it>infection than mice treated with FA; 2) although females appeared to be more resistant to <it>K. pneumoniae </it>than males, O₃exposure significantly increased the susceptibility of females to <it>K. pneumoniae </it>infection to a greater degree than males; 3) alveolar macrophages from O₃-exposed male and female mice have impaired phagocytic ability compared to macrophages from FA-exposed mice; and 4) the O₃-dependent reduction in phagocytic ability is greater in female mice.</p> <p>Conclusion</p> <p>O₃exposure reduces the ability of mice to survive <it>K. pneumoniae </it>infection and the reduced phagocytic ability of alveolar macrophages may be one of the contributing factors. Both events are significantly more pronounced in female mice following exposure to the environmental pollutant, ozone.</p

Неоперабельный гепатоцеллюлярный рак — перспективы лекарственной терапии ленватинибом

There is a number of unresolved issues regarding the systemic therapy administration for hepatocellular carcinoma (HCC). Their solution is facilitated by accumulating real‑world study results. Lenvatinib therapy is a recognized drug with a good efficacy and safety profile for the treatment of HCC. Subanalyses of the REFLECT study showed that the absence of stratification by baseline AFP and baseline liver function, as well as the lack of options for subsequent drug therapy after lenvatinib, also affects the outcomes. Once these factors are taken into account, the hypothesis of superiority of lenvatinib to sorafenib and other drugs can be tested. Real‑world clinical studies have demonstrated positive results of lenvatinib therapy in patients with Child‑Pugh class B liver function, provided recommendations on the sequence of systemic therapy after lenvatinib and on the use of lenvatinib in patients with BCLC stage B, along with considering the possibility of lenvatinib monotherapy and the prospects for its use in patients with nHCC. Further real‑world studies of lenvatinib for HCC in the Russian population are required.В подходах к назначению лекарственной терапии гепатоцеллюлярного рака (ГЦР) есть ряд еще нерешенных вопросов. Их решению способствует накопление результатов исследований в реальной клинической практике. Методом медикаментозной терапии ГЦР с хорошим профилем эффективности и безопасности признана терапия ленватинибом. В субанализах исследования REFLECT показано, что отсутствие стратификации по исходному уровню альфа-фетопротеина и оценке исходной функции печени, а также дефицит опций последующей после назначения ленватиниба медикаментозной терапии оказывают влияние на результаты. Учет этих факторов даст возможность проверить гипотезу превосходства терапии ленватинибом в сравнении с сорафенибом и другими препаратами. В исследованиях реальной клинической практики продемонстрированы положительные результаты применения ленватиниба у пациентов с нарушением функции печени класса B по шкале Чайлд-Пью, даны рекомендации по последовательности системной терапии после ленватиниба, применению ленватиниба у пациентов стадии BCLC B, а также рассмотрены возможности монотерапии ленватинибом и перспективы его применения у пациентов с нГЦК. Необходимы дальнейшие исследования ленватиниба при ГЦР в реальной клинической практике на российской популяции

The results of antitumor dendritic cell vaccines use in patients with metastatic forms of malignant neoplasms and exhausted possibilities of standard therapy

Immunotherapy is one of the most effective and perspective methods of treatment of solid form of malignant neoplasms. The use of control points inhibitors, immunotherapy, dendritic cell ,in particular, for antitumor dendritic cell vaccines based on autologous blood components with an immunological adjuvant is presented in articleИммунотерапия является одним из наиболее эффективных и перспективных методов лечения солидных форм злокачественных новообразований. Использование ингибиторов контрольных точек, иммунотерапии, в частности, к противоопухолевых дендритно-клеточных вакцин на основе аутологичных компонентов крови с иммунологическим адъюванто

Performance of a prototype aerogel counter readout by finemesh photo-tubes

The BaBar experiment, in order to achieve its physics program, requires pion/kaon identification capability up to 4.3 GeV/c. The recent development of new processes has lead to the fabrication of low density silica aerogel with high optical quality. An aerogel threshold counter using the combination of two refractive indices (1.055 and 1.007) can be used to complete the angular coverage of the particle identification system in the forward region of the BaBar experiment. We present final test-beam results on a two-layer aerogel prototype, readout by Hamamatsu fine mesh photo-tubes, as required by the high magnetic field environment of the BaBar experiment, Several configurations have been tested, with different aerogels, photo-tubes and reflective materials. A comparison between data and a detailed Monte Carlo simulation is also presented. The result of the test shows that such a detector can achieve the desired performances